Paper Details

  1. Home
  2. Paper Details

Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients.

Author: De SimoneC, DeliaS, JirilloE, LeuterC, SantiniG, TzantzoglouS, VulloV, di OrioF

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Adding intravenous immunoglobulins to zidovudine therapy for HIV infection significantly reduced the occurrence of pathological events, including opportunistic infections.
Paper Details　
Original Abstract of the Article :
30 patients with HIV infection were enrolled to evaluate the clinical efficacy and toxicity of zidovudine (AZT), 0.5 g/day p.o. (Group A) vs. AZT 0.5 g/day p.o. plus intravenous immunoglobulins (IVIG), 0.4 g/kg of body weight for three consecutive days, followed by one treatment of 0.6 g/kg of body ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/08923979109019716

データ提供：米国国立医学図書館（NLM）

Combating HIV: A New Alliance for a Tough Battle

HIV infection presents a complex challenge for the medical community, and this study explores a promising new approach. Researchers sought to determine the effectiveness of combining intravenous immunoglobulins (IVIG) with zidovudine (AZT) for treating HIV-infected patients. This research is like a camel caravan navigating a sandstorm—combining different approaches to overcome adversity.

IVIG: A Valuable Ally in the Fight

The study revealed that patients treated with AZT and IVIG experienced fewer pathological events compared to those receiving AZT alone. This is like adding an extra camel to the caravan—increasing the carrying capacity and strength of the journey. The results suggest that IVIG acts as a valuable ally in combating HIV infection.

Boosting Immune Defense: A Powerful Combination

IVIG strengthens the immune system, making it more resilient against opportunistic infections. It's like adding extra layers of protection to the caravan—shielding it from harsh conditions. This research suggests that combining IVIG with conventional therapies could significantly improve outcomes for HIV-infected patients.

Dr. Camel's Conclusion

This research showcases the potential benefits of combining IVIG with traditional HIV treatments. This approach offers a valuable weapon in the fight against HIV, helping to improve the lives of patients by bolstering their immune defenses.

Date :
  1. Date Completed 1991-12-16
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1940058

DOI: Digital Object Identifier

10.3109/08923979109019716

Related Literature

Article Analysis
・Effects of azt
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.